CN105209015B - 向皮下脂肪局部递送前列腺素的组合物和方法 - Google Patents

向皮下脂肪局部递送前列腺素的组合物和方法 Download PDF

Info

Publication number
CN105209015B
CN105209015B CN201480027172.6A CN201480027172A CN105209015B CN 105209015 B CN105209015 B CN 105209015B CN 201480027172 A CN201480027172 A CN 201480027172A CN 105209015 B CN105209015 B CN 105209015B
Authority
CN
China
Prior art keywords
certain embodiments
alkyl
optionally substituted
alkenyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480027172.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105209015A (zh
Inventor
M·S·辛格
M·V·卡拉约格鲁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Topokine Therapeutics Inc
Original Assignee
Topokine Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50933526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105209015(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Topokine Therapeutics Inc filed Critical Topokine Therapeutics Inc
Priority to CN201811245298.7A priority Critical patent/CN109966240A/zh
Publication of CN105209015A publication Critical patent/CN105209015A/zh
Application granted granted Critical
Publication of CN105209015B publication Critical patent/CN105209015B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480027172.6A 2013-05-10 2014-05-09 向皮下脂肪局部递送前列腺素的组合物和方法 Expired - Fee Related CN105209015B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811245298.7A CN109966240A (zh) 2013-05-10 2014-05-09 向皮下脂肪局部递送前列腺素的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361822139P 2013-05-10 2013-05-10
US61/822,139 2013-05-10
PCT/US2014/037512 WO2014183045A2 (en) 2013-05-10 2014-05-09 Compositions and methods for topical delivery of prostaglandins to subcutaneous fat

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811245298.7A Division CN109966240A (zh) 2013-05-10 2014-05-09 向皮下脂肪局部递送前列腺素的组合物和方法

Publications (2)

Publication Number Publication Date
CN105209015A CN105209015A (zh) 2015-12-30
CN105209015B true CN105209015B (zh) 2018-11-20

Family

ID=50933526

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480027172.6A Expired - Fee Related CN105209015B (zh) 2013-05-10 2014-05-09 向皮下脂肪局部递送前列腺素的组合物和方法
CN201811245298.7A Pending CN109966240A (zh) 2013-05-10 2014-05-09 向皮下脂肪局部递送前列腺素的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811245298.7A Pending CN109966240A (zh) 2013-05-10 2014-05-09 向皮下脂肪局部递送前列腺素的组合物和方法

Country Status (27)

Country Link
US (5) US9040584B2 (enExample)
EP (3) EP2863886B1 (enExample)
JP (2) JP5930568B1 (enExample)
KR (4) KR20210040180A (enExample)
CN (2) CN105209015B (enExample)
AU (3) AU2014262495B9 (enExample)
BR (1) BR112015028290A2 (enExample)
CA (1) CA2907721C (enExample)
CL (1) CL2015003270A1 (enExample)
CR (1) CR20150652A (enExample)
CY (1) CY1118654T1 (enExample)
DK (2) DK3124015T3 (enExample)
ES (2) ES2670323T3 (enExample)
HU (2) HUE030977T2 (enExample)
IL (2) IL240807A (enExample)
MX (2) MX347969B (enExample)
MY (1) MY183193A (enExample)
NO (1) NO2753788T3 (enExample)
NZ (1) NZ712784A (enExample)
PH (1) PH12015502503B1 (enExample)
PL (2) PL2863886T3 (enExample)
PT (2) PT3124015T (enExample)
RU (1) RU2635864C2 (enExample)
SG (2) SG11201600068WA (enExample)
SI (1) SI2863886T1 (enExample)
WO (1) WO2014183045A2 (enExample)
ZA (1) ZA201507702B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666912B2 (en) 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
KR20170095402A (ko) 2009-11-09 2017-08-22 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
CA2866067C (en) 2011-01-19 2015-04-21 Topokine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
NO2753788T3 (enExample) * 2013-05-10 2018-06-16
US9820993B2 (en) 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen
CA2983942A1 (en) * 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction
CA2988908A1 (en) * 2015-06-09 2016-12-15 Thesan Pharmaceuticals, Inc. Beta-naphthoisoflavones, compositions containing, and uses of, same
US20180179174A1 (en) * 2015-06-23 2018-06-28 Thesan Pharmaceuticals, Inc. 12H-BENZO[b]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME
US20180185325A1 (en) * 2015-06-23 2018-07-05 Thesan Pharmaceuticals, Inc. 12H-BENZO[b]XANTHEN-12-ONES, COMPOSITIONS CONTAINING, AND USES OF, SAME
US10674746B2 (en) 2015-10-27 2020-06-09 Cytozyme Animal Nutrition, Inc. Animal nutrition compositions and related methods
CN108473384A (zh) 2015-10-27 2018-08-31 细胞酶动物营养品公司 动物营养成分及相关方法
CN107773758B (zh) * 2016-08-31 2021-02-26 程辉 一种用于消除皮下脂肪沉积的组合物及其应用
EP4509118A3 (en) * 2018-09-19 2025-05-14 ModernaTX, Inc. High-purity peg lipids and uses thereof
EP3713551B1 (en) 2018-10-16 2023-06-07 Polithera, Inc. Alcohol-based compositions and uses thereof
PL427837A1 (pl) * 2018-11-22 2020-06-01 Gbj Pharma Spółka Z Ograniczoną Odpowiedzialnością Systemy do ciągłego obwodowego podawania latanoprostu dla obniżania ciśnienia śródgałkowego
US20220273765A1 (en) * 2019-04-24 2022-09-01 Follicum Ab Topical formulation
US11452703B2 (en) * 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
JP6855026B1 (ja) * 2020-11-09 2021-04-07 東亜薬品株式会社 タフルプロスト点眼液
KR20240032924A (ko) * 2021-07-12 2024-03-12 오큐소프트, 인코포레이티드 피부 보습 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2228058A1 (en) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
US20100234466A1 (en) * 2006-03-23 2010-09-16 Grosskreutz Cynthia L Compositions and Methods for Reducing Body Fat
CN102639136A (zh) * 2009-11-19 2012-08-15 诺瓦加利制药公司 前列腺素F2α及类似物用于愈合角膜和结膜损害的用途

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
EP0302147A1 (en) 1987-08-03 1989-02-08 The Procter & Gamble Company Topical tanning compositions
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ATE420857T1 (de) 1988-09-06 2009-01-15 Pfizer Health Ab Prostaglandin-derivate zur behandlung von glaukom und ocularer hypertension
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5011062A (en) 1990-05-09 1991-04-30 Delco Electronics Corporation Ultrasonic welding mask
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH07138258A (ja) 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
RU2157689C2 (ru) 1996-07-24 2000-10-20 Панацея Биотек Лтд. Фармацевтические композиции терапевтического антивоспалительного и болеутоляющего средства для местного нанесения и способ их получения
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AU750039B2 (en) 1997-02-04 2002-07-11 Murray A. Johnstone Method of enhancing hair growth
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6232344B1 (en) 1997-12-22 2001-05-15 Alcon Laboratories, Inc. 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
ATE406914T1 (de) 2000-02-10 2008-09-15 Massachusetts Eye & Ear Infirm Photodynamische therapie zur behandlung von augenerkrankungen
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
ES2172415B2 (es) 2000-07-28 2003-11-16 Univ Madrid Complutense Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina.
EA006556B1 (ru) 2001-03-27 2006-02-24 Те Риджентс Оф Те Юниверсити Оф Калифорния Способы, соединения и композиции для борьбы с ожирением и регулирования метаболизма жирных кислот
GB0202159D0 (en) 2002-01-30 2002-03-20 Sensor Highway Ltd OPtical time domain reflectometry
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
JP4387639B2 (ja) * 2002-07-16 2009-12-16 久光製薬株式会社 経皮吸収製剤
US6864282B2 (en) 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
US20040115234A1 (en) 2002-09-24 2004-06-17 Gewirtz Joan T. Cosmetic composition
US8114911B2 (en) 2002-10-23 2012-02-14 Sucampo Ag Prostaglandin compounds for the treatment of obesity
US7074827B2 (en) 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
AU2004224329B2 (en) 2003-03-21 2009-07-09 Nexmed (Holdings), Inc. Compositions and methods for treatment of premature ejaculation
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20050058614A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides
US7070768B2 (en) 2003-09-25 2006-07-04 Allergan, Inc. Method for imparting artificial tan to human skin
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
PL2422789T3 (pl) 2004-05-19 2018-09-28 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Wstrzykiwalna kompozycja zawierająca deoksycholan sodu
ATE412400T1 (de) 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
WO2006082588A2 (en) 2005-02-07 2006-08-10 Pharmalight Inc. Method and device for ophthalmic administration of active pharmaceutical ingredients
CA2602573C (en) 2005-03-31 2013-10-08 Asahi Glass Co Ltd Protective agent for retinal neuronal cell containing prostaglandin f2 .alpha. derivative as active ingredient
BRPI0613034A8 (pt) 2005-07-14 2018-01-02 Lipothera Inc formulação injetável para acúmulo de tecido adiposo, formulação injetável e método para o tratamento de acúmulo de gordura, e, método para reduzir o tecido adiposo.
US20080205679A1 (en) * 2005-07-18 2008-08-28 Darbut Alexander L In-Ear Auditory Device and Methods of Using Same
WO2007026356A2 (en) 2005-08-29 2007-03-08 Healor Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
US9393218B2 (en) 2005-12-23 2016-07-19 Epinamics Gmbh Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers
RU2325912C1 (ru) * 2006-09-06 2008-06-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция противовоспалительного и антимикробного действия в форме мази на гидрофобной основе для лечения кожных заболеваний (варианты)
US8796282B2 (en) 2007-03-28 2014-08-05 Case Western Reserve University Method of treating dermatological disorders
WO2008120249A1 (en) 2007-03-30 2008-10-09 Sifi S.P.A. Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use
US20100074857A1 (en) * 2008-09-23 2010-03-25 Pamela Lipkin Compositions and methods to treat epithelial-related conditions
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
CN101427993A (zh) 2008-11-20 2009-05-13 沈阳万爱普利德医药科技有限公司 前列腺素微乳凝胶制剂及其制备方法
KR20170095402A (ko) 2009-11-09 2017-08-22 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
US20120129789A1 (en) * 2010-11-18 2012-05-24 Steven Yoelin Compositions and methods for hair growth
CA2866067C (en) 2011-01-19 2015-04-21 Topokine Therapeutics, Inc. Uses of certain f-series prostaglandin analogs for treating diabetes and dyslipidemia
BR112013020719B1 (pt) 2011-02-14 2018-04-17 Allergan, Inc. Composições de derivados de bimatoprost tipo éster e métodos
US20120251613A1 (en) * 2011-03-29 2012-10-04 Agila Specialities Pvt. Ltd. Method for treating vitiligo with a prostaglandin analogue
JP2012250950A (ja) * 2011-06-06 2012-12-20 Santen Pharmaceut Co Ltd アデノシン誘導体とプロスタグランジン類の組合せ剤
JP2014520895A (ja) * 2011-07-20 2014-08-25 アラーガン インコーポレイテッド ビマトプロストおよびブリモニジンの固定用量の組み合わせ
US20130035338A1 (en) * 2011-08-05 2013-02-07 Gordon Tang Eyelid treatment
US8426471B1 (en) 2011-12-19 2013-04-23 Topokine Therapeutics, Inc. Methods and compositions for reducing body fat and adipocytes
US20150164765A1 (en) 2012-05-17 2015-06-18 Steven G. Yoelin Compositions and methods for hair growth
KR20140043562A (ko) 2012-09-24 2014-04-10 한국콜마주식회사 무복계면 라타노프로스트 및 그 제조방법
WO2014081941A1 (en) 2012-11-21 2014-05-30 Topokine Therapeutics, Inc. Methods and compositions for locally increasing body fat
NO2753788T3 (enExample) 2013-05-10 2018-06-16
US9820993B2 (en) * 2013-05-15 2017-11-21 Topokine Therapeutics, Inc. Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US10188661B2 (en) 2014-06-27 2019-01-29 Topokine Therapeutics, Inc. Topical dosage regimen

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100234466A1 (en) * 2006-03-23 2010-09-16 Grosskreutz Cynthia L Compositions and Methods for Reducing Body Fat
EP2228058A1 (en) * 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
CN102639136A (zh) * 2009-11-19 2012-08-15 诺瓦加利制药公司 前列腺素F2α及类似物用于愈合角膜和结膜损害的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A Cross-Sectional Survey of the Association between Bilateral Topical Prostaglandin Analogue Use and Ocular Adnexal Features;Mamta Shah等;《PLOS ONE》;20130501;第8卷(第5期);全文 *
拉坦前列素滴眼液治疗青光眼;赵军梅等;《中国新药与临床杂志》;20030131;第22卷(第1期);全文 *

Also Published As

Publication number Publication date
EP3395328A1 (en) 2018-10-31
EP3124015B1 (en) 2018-03-28
CL2015003270A1 (es) 2016-07-08
US20150105462A1 (en) 2015-04-16
MX2020002881A (es) 2020-07-22
KR20160102326A (ko) 2016-08-29
NO2753788T3 (enExample) 2018-06-16
CA2907721C (en) 2016-02-23
WO2014183045A2 (en) 2014-11-13
PT2863886T (pt) 2016-12-02
IL251448A0 (en) 2017-05-29
JP2016135810A (ja) 2016-07-28
EP2863886B1 (en) 2016-08-24
SI2863886T1 (sl) 2017-01-31
RU2635864C2 (ru) 2017-11-16
AU2021221900A1 (en) 2021-09-23
US20180200372A1 (en) 2018-07-19
MY183193A (en) 2021-02-18
US20150231251A1 (en) 2015-08-20
AU2014262495B9 (en) 2019-07-25
HUE030977T2 (en) 2017-06-28
KR20210040180A (ko) 2021-04-12
DK2863886T3 (en) 2016-12-12
KR20150133865A (ko) 2015-11-30
JP2016518416A (ja) 2016-06-23
IL251448B (en) 2021-01-31
NZ730201A (en) 2021-01-29
KR102098987B1 (ko) 2020-04-08
AU2014262495B2 (en) 2019-07-18
CA2907721A1 (en) 2014-11-13
US9849179B2 (en) 2017-12-26
ES2670323T3 (es) 2018-05-30
HUE037405T2 (hu) 2018-08-28
MX347969B (es) 2017-05-18
PH12015502503A1 (en) 2016-02-22
PL2863886T3 (pl) 2017-03-31
AU2019250230A1 (en) 2019-11-07
JP5930568B1 (ja) 2016-06-08
US10556012B2 (en) 2020-02-11
SG10201604659QA (en) 2016-07-28
ZA201507702B (en) 2016-11-30
US9040584B2 (en) 2015-05-26
KR101651450B1 (ko) 2016-08-26
CN109966240A (zh) 2019-07-05
IL240807A (en) 2017-04-30
EP2863886A2 (en) 2015-04-29
BR112015028290A2 (pt) 2017-07-25
ES2604160T3 (es) 2017-03-03
PH12015502503B1 (en) 2016-02-22
PL3124015T3 (pl) 2018-09-28
KR20200037458A (ko) 2020-04-08
SG11201600068WA (en) 2016-02-26
AU2014262495A1 (en) 2015-10-22
MX2015015535A (es) 2016-02-09
EP3124015A1 (en) 2017-02-01
US20200282059A1 (en) 2020-09-10
US20220152206A1 (en) 2022-05-19
NZ712784A (en) 2017-03-31
CN105209015A (zh) 2015-12-30
DK3124015T3 (en) 2018-06-06
WO2014183045A3 (en) 2015-01-29
PT3124015T (pt) 2018-05-10
HK1213200A1 (zh) 2016-06-30
CR20150652A (es) 2016-06-01
CY1118654T1 (el) 2017-07-12
RU2015141767A (ru) 2017-04-06

Similar Documents

Publication Publication Date Title
CN105209015B (zh) 向皮下脂肪局部递送前列腺素的组合物和方法
CN104010643B (zh) 用于减少体脂肪和脂肪细胞的方法和组合物
US20230330105A1 (en) Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
US8883834B2 (en) Methods and compositions for locally increasing body fat
HK1263095A1 (en) Compositions and methods for topical delivery of prostaglandins to subcutaneous fat
HK1213200B (zh) 向皮下脂肪局部递送前列腺素的组合物和方法
HK1233926A1 (en) Compositions and methods for topical delivery of prostaglandins to subcutaneous fat

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1213200

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20181120